Serum tryptase and drug hypersensitivity: why, how and what? A systematic review.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
12
7
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
Serum tryptase, a mast cell marker, provides clues for the mechanism, severity, and management of drug hypersensitivity induced by immunoglobulin E dependent or independent mast cell activation. The interpretation of serum tryptase levels has been challenged during the last 2 years by major advances in tryptase genetics and their rapid incorporation into clinical practice. On the contrary, new pathophysiological insight into nonmast cell-dependent immediate hypersensitivity has been gained. This review provides up-to-date information on the pathophysiology and recommended use and interpretation of tryptase in the context of drug hypersensitivity reactions as a function of their endotype.
Identifiants
pubmed: 37357783
doi: 10.1097/ACI.0000000000000916
pii: 00130832-202308000-00006
doi:
Substances chimiques
Tryptases
EC 3.4.21.59
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
294-299Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316:1622–1626.
Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016; 48:1564–1569.
Alvarez-Cuesta E, Madrigal-Burgaleta R, Broyles AD, et al. Standards for practical intravenous rapid drug desensitization & delabeling: a WAO committee statement. World Allergy Organ J 2022; 15:100640.
Jimenez-Rodriguez TW, Manuel Marco de la Calle F, Lozano-Cubo I, et al. Converter phenotype: a new profile that is not exclusive to taxanes. Front Allergy 2021; 2:785259.
Sadleir PHM, Clarke RC, Goddard CE, et al. Agreement of a clinical scoring system with allergic anaphylaxis in suspected perioperative hypersensitivity reactions: prospective validation of a new tool. Br J Anaesth 2022; 129:670–678.
Jakubovic BD, Sanchez-Sanchez S, Hamadi S, et al. Interleukin-6: a novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association. Allergy 2021; 76:1571–1573.
Yang BC, Castells MC. Utilizing biologics in drug desensitization. Curr Allergy Asthma Rep 2023; 23:1–11.
Sabato V, Michel M, Blank U, et al. Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review. Curr Opin Allergy Clin Immunol 2021; 21:426–434.
Vitte J, Sabato V, Tacquard C, et al. Use and interpretation of acute and baseline tryptase in perioperative hypersensitivity and anaphylaxis. J Allergy Clin Immunol Pract 2021; 9:2994–3005.
Levi-Schaffer F, Gibbs BF, Hallgren J, et al. Selected recent advances in understanding the role of human mast cells in health and disease. J Allergy Clin Immunol 2022; 149:1833–1844.
Brockow K. Detection of drug-specific immunoglobulin E (IgE) and acute mediator release for the diagnosis of immediate drug hypersensitivity reactions. J Immunol Methods 2021; 496:113101.
Lee EY, Jakubovic BD. Interleukin-6 and cytokine release syndrome: a new understanding in drug hypersensitivity reactions. Ann Allergy Asthma Immunol 2023; 130:178–184.
Corbiere A, Loste A, Gaudenzio N. MRGPRX2 sensing of cationic compounds: a bridge between nociception and skin diseases? Exp Dermatol 2021; 30:193–200.
Muraro A, Worm M, Alviani C, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy 2022; 77:357–377.
Liang L, Park KH, Lee JH, Park JW. Causes and diagnostic usefulness of tryptase measurements for anaphylaxis in a Korean tertiary care general hospital. Yonsei Med J 2022; 63:1099–1105.
Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157:215–225.
Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol 2019; 180:44–51.
O’Connell MP, Lyons JJ. Resolving the genetics of human tryptases: implications for health, disease, and clinical use as a biomarker. Curr Opin Allergy Clin Immunol 2022; 22:143–152.
Van Mieghem E, Beyens M, Van Gasse AL, et al. IgE-mediated anaphylaxis to methylprednisolone succinate in a patient with indolent systemic mastocytosis. Allergol Int 2022; 71:552–554.
Lyons JJ, Chovanec J, O’Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol 2021; 147:622–632.
Valent P, Hartmann K, Bonadonna P, et al. Mast cell activation syndromes: Collegium Internationale Allergologicum Update 2022. Int Arch Allergy Immunol 2022; 183:693–705.
Lyons JJ, Greiner G, Hoermann G, Metcalfe DD. Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions. J Allergy Clin Immunol Pract 2022; 10:1964–1973.
Lyons JJ. Inherited and acquired determinants of serum tryptase levels in humans. Ann Allergy Asthma Immunol 2021; 127:420–426.
Glover SC, Carter MC, Korosec P, et al. Clinical relevance of inherited genetic differences in human tryptases: hereditary alpha-tryptasemia and beyond. Ann Allergy Asthma Immunol 2021; 127:638–647.
Giannetti MP, Weller E, Bormans C, et al. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis. Ann Allergy Asthma Immunol 2021; 126:655–660.
Bonadonna P, Olivieri F, Jarkvist J, et al. Nonsteroidal anti-inflammatory drug-induced anaphylaxis infrequent in 388 patients with mastocytosis: a two-center retrospective cohort study. Front Allergy 2022; 3:1071807.
Kacar M, Rijavec M, Selb J, Korosec P. Clonal mast cell disorders and hereditary alpha-tryptasemia as risk factors for anaphylaxis. Clin Exp Allergy 2023; 53:392–404.
Rama TA, Morgado JM, Henriques A, et al. Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features. Clin Transl Allergy 2022; 12:e12132.
Steveling-Klein EH, Mateluna CM, Meienberg A, et al. Management of hypersensitivity reactions to nondextran iron products: new insights into predisposing risk factors. J Allergy Clin Immunol Pract 2021; 9:2406–2414. e2402.
Foer D, Wien M, Karlson EW, et al. Patient characteristics associated with reactions to Mrgprx2-activating drugs in an electronic health record-linked Biobank. J Allergy Clin Immunol Pract 2023; 11:492–499. e492.
Ebo DG, De Puysseleyr LP, Van Gasse AL, et al. Mast cell activation during suspected perioperative hypersensitivity: a need for paired samples analysis. J Allergy Clin Immunol Pract 2021; 9:3051–3059. e3051.
Wohrl S, Ostermayer C, Sesztak-Greinecker G, et al. Drug-specific history, skin and in vitro tests can reduce the need for drug provocation tests in betalactam-hypersensitivity. Allergol Int 2021; 70:244–251.
Mori F, Crisafulli G, Bianchi A, et al. Drugs and vaccines hypersensitivity in children with mastocytosis. J Clin Med 2022; 44:341–364.
Huang WY, Chiu TM, Kuo SF, et al. A case report of a 3-year-old child with anaphylactic shock after a diclofenac suppository confirmed by serial tryptase and a basophil activation test. Front Pediatr 2021; 9:802715.
Alvarado D, Maurer M, Gedrich R, et al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy 2022; 77:2393–2403.
Waters AM, Park HJ, Weskamp AL, et al. Elevated basal serum tryptase: disease distribution and variability in a regional health system. J Allergy Clin Immunol Pract 2022; 10:2424–2435.e5.
Vitte J, Sjolander A, Rydell N, et al. Tryptase reference values in a Swedish middle-aged general population and association with diabetes mellitus. Clin Exp Allergy 2022; 52:1330–1333.
Michel M, Klingebiel C, Vitte J. Tryptase in type I hypersensitivity. Ann Allergy Asthma Immunol 2023; 130:169–177.
Brockow K, Plata-Nazar K, Lange M, et al. Mediator-related symptoms and anaphylaxis in children with mastocytosis. Int J Mol Sci 2021; 22:2684–2698.
Elst J, van der Poorten MM, Van Gasse AL, et al. Tryptase release does not discriminate between IgE- and MRGPRX2-mediated activation in human mast cells. Clin Exp Allergy 2022; 52:797–800.
Srisuwatchari W, Tacquard CA, Borushko A, et al. Diagnostic performance of serial serum total tryptase measurement to differentiate positive from negative allergy testing among patients with suspected perioperative hypersensitivity. Clin Exp Allergy 2022; 52:334–344.
Sverrild A, Carruthers J, Murthee KG, et al. Diagnostic value of a medical algorithm for investigation of perioperative hypersensitivity reactions. Allergy 2023; 78:225–232.
Garvey LH, Melchiors BB, Ebo DG, et al. Medical algorithms: diagnosis and investigation of perioperative immediate hypersensitivity reactions. Allergy 2020; 75:2139–2142.
Mateja A, Wang Q, Chovanec J, et al. Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. J Allergy Clin Immunol 2022; 149:1010–1017. e1010.
Slot MC, Claessen LHJ, Bons JAP, et al. Tryptase reference ranges are age-dependent in a large population-based cohort. Allergy 2022; 77:2833–2834.
Ritter S, Fowler J, Adam Lieberman J. Temporal variation of tryptase and interlaboratory variability. Ann Allergy Asthma Immunol 2022; 129:640–642.
Spoerl D, Docquier M, Coattrenec Y, Seebach JD. Patients with elevated basal tryptase serum levels should be tested for hereditary alpha-tryptasemia. Eur Ann Allergy Clin Immunol 2022; 54:242–244.
Chovanec J, Tunc I, Hughes J, et al. Genetically determining individualized clinical reference ranges for the biomarker tryptase can limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv 2023; 7:1796–1810.
Cahill KN, Wu P, Milne GL, et al. Mediator production and severity of aspirin-induced respiratory reactions: impact of sampling site and body mass index. J Allergy Clin Immunol 2022; 150:170–177. e176.
Buchheit KM, Lewis E, Gakpo D, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2021; 148:574–584.
Meir LR, Habbsa S, Waqar O, et al. Anaphylaxis among elderly emergency department patients in a large health system in New York. Ann Allergy Asthma Immunol 2022; 129:63–70. e63.
Seth N, Tuano KT, Buheis M, et al. Serum tryptase levels in pediatric mastocytosis and association with systemic symptoms. Ann Allergy Asthma Immunol 2020; 125:219–221.
Belhocine W, Ibrahim Z, Grandne V, et al. Total serum tryptase levels are higher in young infants. Pediatr Allergy Immunol 2011; 22:600–607.
Carra S, Schatz M, Mertes PM, et al. Anaphylaxis and pregnancy: a systematic review and call for public health actions. J Allergy Clin Immunol Pract 2021; 9:4270–4278.